Sema4, Mount Sinai, Sanofi announce launch of new collaborative asthma study

Sema4, a patient-centered predictive health company, and the Mount Sinai Health System today announced the launch of a five-year collaborative study with Sanofi designed to provide new insights into the biological mechanisms and other factors implicated in asthma. The project will follow nearly 1,200 people with asthma and collect a range of data from traditional clinical data to genomics, immunological, environmental, and sensor data from mobile devices to enable sophisticated analysis and advanced network modeling of this complex disease.
Asthma is the most prevalent chronic respiratory disease, affecting more than 350 million people worldwide and causing approximately 400,000 deaths worldwide annually1. Evidence shows that the prevalence of asthma is increasing, and along with it both direct healthcare costs as well as indirect costs from loss of productivity and early disability.
"Despite advances in recent years, we still see many patients struggling with asthma, so there is still a tremendous need for innovation to reduce the burden of this disease," said Linda Rogers, MD, Associate Professor and Clinical Director of the Adult Asthma Program at the Mount Sinai - National Jewish Health Respiratory Institute. "With one of the largest asthma programs in the region, caring for patients across the spectrum of severity of asthma, the Mount Sinai - National Jewish Health Respiratory Institute will play a crucial role in this partnership to advance our understanding of asthma and develop personalized therapies for our patients."